Buy article

Volume: 0 - Issue: 0

First page: 0 - Last page: 0

P.W. Hellings - E. De Corso - V. Backer - M. Bernal-Sprekelsen - Y. Chan - D.M. Conti - M.E. Cornet - W.J. Fokkens - P. Gevaert - J. Han - C. Hopkins - B.N. Landis - S. Lau - S. Lee - V.J. Lund - J. Mullol - A. Peters - S. Schneider - B. Senior

DOI: 10.4193/Rhin24.457

Remission has recently been proposed as the new goal of care in CRSwNP or Nasal Polyp Syndrome by the European Forum for Research and Education in Allergy and Airway Diseases / European Position Paper on Rhinosinusitis and Nasal Polyps (EUFOREA/EPOS) (1,2) as well as by global leaders in Rhinology (3). In CRSwNP, remission is defined as a prolonged state of control, without bothersome symptoms reported by the patient for at least 12 months, without the need for either oral corticosteroids or endoscopic sinus surgery (ESS), and without endoscopic signs of active disease (1). This new goal of care is to be encouraged by the ENT community and CRSwNP patients as persistent symptoms unalleviated by historical approaches (4,5) can be reduced by new
therapies including biologics. The goal of therapy for CRSwNP has long been to achieve control, with Visual Analogue Scale (VAS) and Sino-Nasal Outcome Test (SNOT-22) scores guiding physicians towards a step-up treatment aiming for control (6,7).

Rhinology 0-0: 0-0, 0000